Inhibition of carcinoma cell motility by epoxyeicosatrienoic acid (EET) antagonists

Cancer Science

Volumn 101, Issue 12, 2010, Pages 2629-2636

  Nithipatikom, Kasem ^a   Brody, Daniel M ^a   Tang, Alan T ^a   Manthati, Vijaya L ^b   Falck, John R ^b   Williams, Carol L ^a   Campbell, William B ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11,12 EPOXY 5,8,14 ICOSATRIENOIC ACID; 14,15 EPOXEICOSA 5 ENOIC METHYLSULFONYLIMIDE; 14,15 EPOXYEICOSA 5 ENOIC ACID; 14,15 EPOXYEICOSA 5 ENOIC ACID 2 [2 (3 HYDROXYPROPOXY)ETHOXY]ETHYL ESTER; 2 MORPHOLINO 8 PHENYLCHROMONE; ACTIN; AG 494; ANTINEOPLASTIC AGENT; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2J2; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPOXYICOSATRIENOIC ACID; MESSENGER RNA; MYOSIN; N METHYLSULFONYL 6 (2 PROPARGYLOXYPHENYL)HEXANAMIDE; OXIDOREDUCTASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOMA CELL; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL STRAIN LNCAP; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; MALE; METABOLITE; MICROFILAMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

8,11,14-EICOSATRIENOIC ACID; BLOTTING, WESTERN; CARCINOMA; CELL LINE, TUMOR; CELL MOVEMENT; CYTOCHROME P-450 ENZYME SYSTEM; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MALE; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 78449289923     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01713.x     Document Type: Article

References (32)

1. Rifkind AB, Lee C, Chang TK et al. Arachidonic acid metabolism by human cytochrome P450s 2C8, 2C9, 2E1, and 1A2: regioselective oxygenation and evidence for a role for CYP2C enzymes in arachidonic acid epoxygenation in human liver microsomes. Arch Biochem Biophys 1995; 320: 380-9.
2. Lundblad MS, Stark K, Eliasson E et al. Biosynthesis of epoxyeicosatrienoic acids varies between polymorphic CYP2C enzymes. Biochem Biophys Res Commun 2005; 327: 1052-7.
3. Imaoka S, Hashizume T, Funae Y. Localization of rat cytochrome P450 in various tissues and comparison of arachidonic acid metabolism by rat P450 with that by human P450 orthologs. Drug Metab Pharmacokinet 2005; 20: 478-84.
4. Nishimura M, Yaguti H, Yoshitsugu H et al. Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi 2003; 123: 369-75.
5. Michaelis UR, Fisslthaler B, Barbosa-Sicard E et al. Cytochrome P450 epoxygenases 2C8 and 2C9 are implicated in hypoxia-induced endothelial cell migration and angiogenesis. J Cell Sci 2005; 118: 5489-98.
6. Wang Y, Wei X, Xiao X et al. Arachidonic acid epoxygenase metabolites stimulate endothelial cell growth and angiogenesis via mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways. J Pharmacol Exp Ther 2005; 314: 522-32.
7. Yang W, Tuniki VR, Anjaiah S et al. Characterization of epoxyeicosatrienoic acid binding site in U937 membranes using a novel radiolabeled agonist, 20-125i-14, 15-epoxyeicosa-8(Z)-enoic acid. J Pharmacol Exp Ther 2008; 324: 1019-27.
8. Yang W, Holmes BB, Gopal VR et al. Characterization of 14, 15-epoxyeicosatrienoyl-sulfonamides as 14, 15-epoxyeicosatrienoic acid agonists: use for studies of metabolism and ligand binding. J Pharmacol Exp Ther 2007; 321: 1023-31.
9. Gauthier KM, Jagadeesh SG, Falck JR et al. 14, 15-epoxyeicosa-5(Z)-enoic-mSI: a 14, 15- and 5, 6-EET antagonist in bovine coronary arteries. Hypertension 2003; 42: 555-61.
10. Gauthier KM, Deeter C, Krishna UM et al. 14, 15-Epoxyeicosa-5(Z)-enoic acid: a selective epoxyeicosatrienoic acid antagonist that inhibits endothelium-dependent hyperpolarization and relaxation in coronary arteries. Circ Res 2002; 90: 1028-36.
11. Ragavan N, Hewitt R, Cooper LJ et al. CYP1B1 expression in prostate is higher in the peripheral than in the transition zone. Cancer Lett 2004; 215: 69-78.
12. Yokose T, Doy M, Taniguchi T et al. Immunohistochemical study of cytochrome P450 2C and 3A in human non-neoplastic and neoplastic tissues. Virchows Arch 1999; 434: 401-11.
13. Enayetallah AE, French RA, Grant DF. Distribution of soluble epoxide hydrolase, cytochrome P450 2C8, 2C9 and 2J2 in human malignant neoplasms. J Mol Histol 2006; 37: 133-41.
14. Michaelis UR, Xia N, Barbosa-Sicard E et al. Role of cytochrome P450 2C epoxygenases in hypoxia-induced cell migration and angiogenesis in retinal endothelial cells. Invest Ophthalmol Vis Sci 2008; 49: 1242-7.
15. Jiang JG, Ning YG, Chen C et al. Cytochrome p450 epoxygenase promotes human cancer metastasis. Cancer Res 2007; 67: 6665-74.
16. Tew GW, Lorimer EL, Berg TJ et al. SmgGDS regulates cell proliferation, migration, and NF-{kappa}B transcriptional activity in non-small cell lung carcinoma. J Biol Chem 2008; 283: 963-76.
17. Nithipatikom K, Grall AJ, Holmes BB et al. Liquid chromatographic-electrospray ionization-mass spectrometric analysis of cytochrome P450 metabolites of arachidonic acid. Anal Biochem 2001; 298: 327-36.
18. Nithipatikom K, Endsley MP, Isbell MA et al. 2-Arachidonoylglycerol: a novel inhibitor of androgen-independent prostate cancer cell invasion. Cancer Res 2004; 64: 8826-30.
19. Endsley MP, Aggarwal N, Isbell MA et al. Diverse roles of 2-arachidonoylglycerol in invasion of prostate carcinoma cells: location, hydrolysis and 12-lipoxygenase metabolism. Int J Cancer 2007; 121: 984-91.
20. Mimeault M, Pommery N, Wattez N et al. Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor down-regulation and ceramide production. Prostate 2003; 56: 1-12.
21. Yang P, Collin P, Madden T et al. Inhibition of proliferation of PC3 cells by the branched-chain fatty acid, 12-methyltetradecanoic acid, is associated with inhibition of 5-lipoxygenase. Prostate 2003; 55: 281-91.
22. Ohl F, Jung M, Xu C et al. Gene expression studies in prostate cancer tissue: which reference gene should be selected for normalization? J Mol Med 2005; 83: 1014-24.
23. Choudhary D, Jansson I, Stoilov I et al. Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab Dispos 2004; 32: 840-7.
24. Zhou W, Grandis JR, Wells A. STAT3 is required but not sufficient for EGF receptor-mediated migration and invasion of human prostate carcinoma cell lines. Br J Cancer 2006; 95: 164-71.
25. Marcoux N, Vuori K. EGF receptor activity is essential for adhesion-induced stress fiber formation and cofilin phosphorylation. Cell Signal 2005; 17: 1449-55.
26. Schwartz MA, Baron V. Interactions between mitogenic stimuli, or, a thousand and one connections. Curr Opin Cell Biol 1999; 11: 197-202.
27. Jiang JG, Chen CL, Card JW et al. Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors. Cancer Res 2005; 65: 4707-15.
28. Zhang B, Cao H, Rao GN. Fibroblast growth factor-2 is a downstream mediator of phosphatidylinositol 3-kinase-Akt signaling in 14, 15-epoxyeicosatrienoic acid-induced angiogenesis. J Biol Chem 2006; 281: 905-14.
29. Skogseth H, Larsson E, Halgunset J. The invasive behaviour of prostatic cancer cells is suppressed by inhibitors of tyrosine kinase. Apmis 2006; 114: 61-6.
30. Chen JK, Capdevila J, Harris RC. Heparin-binding EGF-like growth factor mediates the biological effects of P450 arachidonate epoxygenase metabolites in epithelial cells. Proc Natl Acad Sci U S A 2002; 99: 6029-34.
31. Cheng LM, Jiang JG, Sun ZY et al. The epoxyeicosatrienoic acid-stimulated phosphorylation of EGF-R involves the activation of metalloproteinases and the release of HB-EGF in cancer cells. Acta Pharmacol Sin 2010; 31: 211-8.
32. Dhanasekaran A, Gruenloh SK, Buonaccorsi JN et al. Multiple antiapoptotic targets of the PI3K/Akt survival pathway are activated by epoxy-eicosatrienoic acids to protect cardiomyocytes from hypoxia/anoxia. Am J Physiol Heart Circ Physiol 2008; 294: H724-35.